Vaccine compositions comprising brucella strains and methods thereof
AssigneeThe Texas A&M University System
InventorsPaul DE FIGEIREDO, Jim SONG, Tom FICHT, Robert ALANIZ
Life of this patent
Estimating the term…
Abstract
The present disclosure provides pharmaceutical compositions comprising a live attenuated bacterial strain of Brucella melitensis, in particular a live attenuated bacterial strain of Brucella melitensis is Brucella melitensis 16M ΔvjbR (BmΔvjbR). Methods of utilizing the live attenuated bacterial strain of Brucella melitensis for treatment of a patient are also provided, including wherein the patient is in need of treatment for cancer, an autoimmune disorder, and/or an inflammatory disorder.
Claims39
A pharmaceutical composition comprising a live attenuated bacterial strain of Brucella melitensis.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a patient, said method comprising the step of administering a pharmaceutical composition comprising a live attenuated bacterial strain of Brucella melitensis to the patient.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A transgenic attenuated Brucella melitensis strain, said strain comprising a mutation in a virulence gene of said strain, said mutation selected from the group consisting of vjbR, asp14, and mucR wherein said mutation inactivates the virulence gene;
- and a nucleic acid encoding tryptophanase (tnaA).
Dependencies are inferred from the claim text.